Endometrial Cancer Clinical Trials

Find Endometrial Cancer Clinical Trials Near You

Non-Invasive Strategies for Early Detection of Uterine Cancer in Patients With Abnormal Uterine Bleeding

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The study goal is to investigate a non-invasive approach to predict endometrial cancer (EC) risk, better understand disease progression and identify opportunities for intervention. This two-part case-cohort prospective study will recruit patients whose abnormal uterine bleeding is being evaluated via endometrial biopsy. Participants will complete an online health questionnaire, and a subset will be invited to self-collect vaginal samples for sequencing. Selected sequenced participants will be invited for longitudinal monitoring (questionnaires, wearable fitness tracker) and an additional vaginal self-collection to identify persistent genetic mutations or microbiome alterations 6-8 months later.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 40
Healthy Volunteers: t
View:

⁃ Study Part A:

• 40 years and older

• Experiencing unexplained abnormal uterine bleeding (i.e., not from IUD, etc.)

• Have an intact uterus

• Referred for an endometrial biopsy

⁃ Study Part B/Longitudinal monitoring:

• Those selected for sequencing (from Part A) and who retained their uterus.

Locations
Other Locations
Canada
VGH Research Pavilion
RECRUITING
Vancouver
Contact Information
Primary
Aline Talhouk, PhD
a.talhouk@ubc.ca
+1 (604) 875-4111
Backup
Jennifer Ellis-White
jelliswh@student.ubc.ca
+1 (604) 875-4111
Time Frame
Start Date: 2024-10-10
Estimated Completion Date: 2027-01
Participants
Target number of participants: 1000
Treatments
EIN/EC BIOPSY RESULT
Vaginal samples sequenced. Participation ends here.
EH BIOPSY RESULT
Vaginal samples sequenced. Subset invited to move on to longitudinal monitoring and samples sequenced for 6 additional months.
NEGATIVE BIOPSY RESULT
Control for natural and spontaneous changes in vaginal samples sequenced. Random subset selected to move on to longitudinal monitoring and samples sequenced for 6 additional months.
Related Therapeutic Areas
Sponsors
Collaborators: Canadian Institutes of Health Research (CIHR)
Leads: University of British Columbia

This content was sourced from clinicaltrials.gov